Paul Hudson, Sanofi CEO (Sipa via AP Images)
March 15, 2022 07:36 AM EDT
R&D

Root­ing for a come-from-be­hind win, Black­stone in­fus­es $330M in­to Sanofi's CD38 de­vel­op­ment plan

Amber Tong

Sanofi is get­ting a lit­tle bit of help to ex­pand its Sar­clisa fran­chise, with Black­stone Life Sci­ences putting down close to $330 mil­lion (€300 mil­lion) …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times